Sri Pranita Cherukuri

Dr. Sri Pranita Cherukuri

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2024
Verified
Journal Article
Open access
PDF file
RCRebecca Caruana
Rebecca Caruana
HAHira Aslam
Hira Aslam
NANosheen Akhtar
Nosheen Akhtar
WAWaqas Ahmad
Waqas Ahmad
TRTariq Rafique Rana
Tariq Rafique Rana
MAMuhammad Saad Arshad
Muhammad Saad Arshad
Introduction: Treating illnesses caused by enterobacteria is increasingly challenging due to the ineffectiveness of antibiotics in combating pathogens or promoting reticuloendothelial system cell phagocytosis, especially for bacteria that colonize and grow inside phagocytic cells. Certain antibiotics are unable to penetrate cells or are limited by the plasma membrane. Consequently, there is a scientific effort to develop new therapeutic strategies to overcome these challenges. Lipid nanocarriers, such as liposomes, can encapsulate antibiotics to enhance their delivery, targeting, and efficacy. Liposomes aim to improve the specificity of release, concentration of compounds at the target site, maintenance of drug plasma concentration, and preservation of active components. This review aims to outline the key characteristics of liposomes and emphasize the benefits of using these lipid vesicles to deliver antibiotics against illnesses caused by enterobacteria. Methodology: A literature review was conducted by searching national and international electronic databases for articles published between 2012 and 2023. Articles were selected based on the following descriptors: bacterial resistance, nanotechnology, gram-negative bacteria, and antibiotics. Findings: Antibacterial activity has been demonstrated for cationic and stealth liposomes, primarily composed of cholesterol, PEG, phosphatidylcholine, and carboxymethyl chitosan encapsulating drugs such as amoxicillin, ciprofloxacin, cloxacillin, vancomycin, azithromycin, amoxicillin, cefepime, gentamicin, and cefotaxime. Liposomes containing polymyxin B, azithromycin, chloramphenicol, and gentamicin have shown improved antibiofilm efficacy against enterobacteria compared to non-encapsulated pharmaceuticals. Conclusion: The findings highlight the significant therapeutic potential of liposomes in the management of enterobacteria-related illnesses.

2 July 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
SCSri Pranita Cherukuri
Sri Pranita Cherukuri
Background/Objectives: Cancer interception trials require intermediate endpoints capable of detecting biologic activity before cancer incidence, progression, or survival outcomes become measurable. Ki-67, a nuclear marker of cellular proliferation, is widely used as a prognostic and pharmacodynamic biomarker across multiple malignancies. This review evaluates the evidence supporting Ki-67 modulation as an intermediate endpoint in cancer interception and prevention research. Methods: Published clinical studies reporting pre- and post-intervention Ki-67 changes were reviewed, with emphasis on interception, prevention, and presurgical window-of-opportunity trials involving dietary, phytochemical, and endocrine interventions. Results: Evidence from prostate, lung, and breast cancer settings demonstrates that Ki-67 is responsive to biologic intervention. In CAPFISH-3, a high omega-3/low omega-6 dietary intervention plus fish oil reduced Ki-67 by 15% in men undergoing active surveillance for prostate cancer, whereas Ki-67 increased by 24% in controls. In a randomized phase II lung premalignancy trial, a sulforaphane-producing intervention reduced bronchial Ki-67 by 20%, compared with a 65% increase with placebo. Presurgical breast cancer studies, including flaxseed supplementation and endocrine therapy trials, further demonstrated significant reductions in Ki-67 over short intervention periods. However, changes in Ki-67 were not consistently accompanied by short-term histologic or clinical endpoint improvements. Conclusions: Current evidence supports Ki-67 as a promising intermediate pharmacodynamic endpoint capable of detecting biologic activity in cancer interception studies. Nevertheless, variability in assessment methods, tissue sampling, and uncertainty regarding long-term clinical correlation limit its current role as a surrogate endpoint. Additional prospective validation is required before Ki-67 can be adopted as a standardized endpoint in cancer interception research.

26 September 2024
Verified
Journal Article
Open access
PDF file
AOAliu Olalekan Olatunji
Aliu Olalekan Olatunji
RTRafique Tariq
Rafique Tariq
HAHira Aslam
Hira Aslam
NANaseem Akhter
Naseem Akhter
BGBaneen Gabble
Baneen Gabble
TRTariq Rafique Rana
Tariq Rafique Rana
Objective: To investigate awareness, familiarity and perceptions of targeted drug delivery systems in nanomedicine between demographic sub-groups. The objective of this research is to investigate how gender, education level and occupation affect attitudes towards nanomedicine with an emphasis on applications in oncology and others. Furthermore, the research explores some of the ethical issues connected to these new technologies. Aim: The major aim of the study was to explore demographics associated with familiarization with nanomedicine, awareness regarding targeted drug delivery systems and perception towards effectiveness and safety. It also seeks to understand ethical questions and describes how these are situated among differing levels of perceptiveness and acquaintance. Methodology: This cross-sectional study was conducted to measure the overall eHealth literacy scale among 200 participants through an online survey. Closed-ended and Likert scale questions were used in the survey which sought information on demographics as well as awareness, familiarity with nanomedicine or perceptions of them. The data were analyzed using selected statistical tests: Chi-square, ANOVA, T-test and by a couple of tests (Spearman correlation), Mann-Whitney U test or Kruskal-Wallis H. These tests were employed to establish connections and differences in the variables under study. Results: The Chi-square test showed no significant relation between gender and knowledge of targeted drug delivery systems (Chi2 = 0.981, p = 0.612). ANOVA test analysis on optimism about the future of nanomedicine versus different educational levels failed to show any significant difference type F = 0.147; p= 0.964). On a T-test analysis, awareness of the broader applications of nanomedicine and knowledge level was different two (T = -2.498, p = 0.013). The Spearman correlation between familiarity and effectiveness perceptions was weak, and non-significant (r = -0.111; p = 0.119). However, no differences were found for ethical concerns about nanomedicine in terms of hearing the term “targeted drug delivery systems” (U = 4941.0, p =.900 according to Mann-Whitney U test). The Kruskal Wallis H test discovered no significant interceptional variance concerning the number of challenges identified (H = 2.804, p =.591). Practical Implications: This study clearly shows that the awareness and familiarity of people are crucial to its acceptance for use in a clinical setting. Engineering education programs aimed at a more accessible spectrum of nanomedicine applications, such as those beyond oncology, could also help bring public awareness and support for these technologies. Furthermore, with involvement of scientists from a wide range of areas also openly considering the ethical issues might go some way to restoring public trust and confidence in nanomedicine. Importance: Examining the social and ethical aspects of nanomedicine adds importance to this study, as specific questions regarding familiarity with and awareness about targeted drug delivery systems have not been studied in different demographic groups. Further, it contributes fresh angles on the ethical landscape surrounding nanomedicine a topic that remains largely uncharted by Schaefer et al. Conclusions: This study suggests that awareness is an important predictor of familiarity with nanomedicine, but not perception about the effectiveness and thus other factors i.e. trust in benefits vs ethical issues seem to be substantially evidenced by a greater predictive strength than awareness or support for development in making sense of this response disparity across countries/regions. This universal persistence of ethical challenges across tiers of awareness necessitates continued incisive dialogue and established principles to govern the safe deployment with the integrity of nanomedicine. The findings can greatly influence public health policy and clinical practice, highlighting the necessity of interdisciplinary strategies to overcome these barriers to boost nanomedicine utilization.

30 September 2026 in World Nutrition
Verified
Journal Article
Open access
PDF file
SCSri Pranita Cherukuri
Sri Pranita Cherukuri
Purpose: This commentary argues that food-as-medicine communication in chronic disease prevention should be evidence-calibrated, equity-centered, culturally responsive, and clinically responsible. The article focuses on how clinicians, public health organizations, and nutrition communicators can discuss food, dietary patterns, food access, and disease prevention without overstating certainty or implying that diet replaces medical care. Approach: The commentary synthesizes selected peer-reviewed literature, national and international nutrition guidance, and public health ethics principles into a practical communication framework. The synthesis distinguishes mechanistic, observational, randomized, implementation, and guideline-level evidence, and combines these evidence categories with ethical considerations related to autonomy, nonmaleficence, justice, culture, and social determinants of health. The central argument is that food-as-medicine can support chronic disease prevention only when public messages clearly separate evidence-based assertions from opinion, acknowledge uncertainty, address food access barriers, avoid disease-cure claims, and encourage clinician oversight for high-risk patients. The article proposes practical safeguards for ethical communication, including evidence-proportionate wording, plain-language uncertainty statements, separation of dietary-pattern guidance from supplement or wellness-product claims, attention to affordability and cultural relevance, and explicit integration with standard medical care.

4 December 2024 in Frontiers in Health Informatics
Verified
Journal Article
Open access
PDF file
DFDarlington David Faijue
Darlington David Faijue
FSFaisal Saeed
Faisal Saeed
HLHatim Lokhandwala
Hatim Lokhandwala
HAHassanien Mohammed Alwash
Hassanien Mohammed Alwash
MAMansoor Ali
Mansoor Ali
SCSri Pranita Cherukuri
Sri Pranita Cherukuri
Background: Hepatitis E is a significant public health concern, especially in developing countries, due to its association with waterborne outbreaks. It accounts for a large proportion of enteric-transmitted liver diseases worldwide. In developed nations, cases of hepatitis E are rare and typically linked to travellers from endemic regions or individuals without identifiable risk factors. Objective: To provide an overview of the hepatitis E virus (HEV), including its virology, transmission, zoonotic potential, and treatment options. Methods: A review of current literature on HEV epidemiology, virology, modes of transmission, and treatment approaches, with a focus on genotype distribution and its impact on public health. Results: HEV is a single-stranded, non-enveloped RNA virus with one serotype and four genotypes. Genotypes 1 and 2 are primarily found in developing countries and exclusively infect humans, while genotypes 3 and 4, common in industrialized countries, infect humans and other mammals, especially pigs. HEV is increasingly recognized as a zoonotic.

25 September 2024
Verified
Journal Article
Open access
PDF file
KUKhalida Unar
Khalida Unar
RJRabia Jaffar
Rabia Jaffar
MEMuhammad Suleman Ejaz
Muhammad Suleman Ejaz
SCSri Pranita Cherukuri
Sri Pranita Cherukuri
TRTariq Rafique Rana
Tariq Rafique Rana
SSSyed Baha Ud Din Shah
Syed Baha Ud Din Shah
Background: Thyroid neoplasms exhibit a diverse evolutionary trajectory, suggesting distinct pathways from normal thyroid cells to malignancy. Methods: Molecular changes initiating follicular adenoma formation likely precede progression to follicular cancer. Papillary carcinoma, however, may evolve via a separate pathway, bypassing follicular adenoma. Subsequent genetic alterations can lead to anaplastic cancer, significantly impacting prognosis. Results: Genome instability predisposes thyroid tumour cells to molecular alterations, with proto-oncogene changes occurring early and suppressor gene mutations typically occurring later. These changes contribute to aggressive or invasive behaviours, potentially influencing clinical outcomes. Conclusion: Advances in understanding genetic alterations in thyroid oncogenesis offer promise for enhancing diagnostic accuracy and treatment efficacy, thereby improving outcomes for thyroid malignancies.